The Europe Newborn Screening Market would witness market growth of 6.2% CAGR during the forecast period (2022-2028).
Before the newborn leaves the hospital, usually within the first two days of his or her life, a blood sample is taken from the baby's ankle. It is recommended that a blood sample be taken after the first 24 hours of life. It is possible to examine newborns within 24 hours because mothers and newborns can sometimes be discharged within one day. If this happens, doctors advise waiting one to two weeks before collecting another sample.
Several health problems discovered by neonatal screening are hereditary. Inherited refers to something that is passed on from one generation down the generations from one parent to the next. Genes are instructions for how the human body grows and works that are stored in the cells of the body. Whenever one kid in a household has a hereditary health issue, the chances of a brother or sister developing the same illness are higher than if no one in the family has it. A genetic counselor is someone who has been trained to explain genes, birth abnormalities, and other medical disorders that run-in families, as well as how they can affect parents' health and the health of the kid. Hearing loss may not always be hereditary. Infection during pregnancy can cause it. In this scenario, it is unusual for it to occur again in a subsequent pregnancy.
Pregnant women with health insurance in Germany are often offered three routine ultrasound scans at no additional cost. Occasionally, they are referred to as screening tests. These three standard ultrasound scans are used to determine if the pregnancy and the child's growth are progressing correctly. In general, 96 to 98 percent of pregnant women give delivery to a healthy baby. However, anomalies detected by ultrasound may necessitate further investigations and, in certain cases, difficult judgments.
The Germany market dominated the Europe Newborn Screening Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $100.2 Million by 2028. The UK market is experiencing a CAGR of 5.3% during (2022 - 2028). Additionally, The France market is exhibiting a CAGR of 7% during (2022 - 2028).
Based on Product Type, the market is segmented into Consumables and Instrument. Based on Test Type, the market is segmented into Blood Test, Hearing Screening Test, and Heart screening. Based on End User, the market is segmented into Hospitals and Clinical Laboratories. Based on Technology, the market is segmented into Tandem Mass Spectrometry (TMS), Molecular Assays, Immunoassays & Enzymatic Assays, Hearing Screen Technology, Pulse Oximetry Screening Technology, Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Newborn Screening Market Size will Hit $1.6 Billion by 2028, at a CAGR of 6.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include General Electric (GE) Co. (GE Healthcare), F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Natus Medical Incorporated, Masimo Corporation, Waters Corporation, PerkinElmer, Inc., AB Sciex LLC (Danaher Corporation), Medtronic PLC (Covidien plc), Trivitron Healthcare Pvt. Ltd.
By Product Type
By Test Type
By End User
By Technology
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 